Four-week omeprazole treatment of non-erosive reflux disease in a Japanese population
Study identifier:D9587C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomised, parallel-group, multicentre, Phase III study to compare the efficacy of omeprazole 20mg and 10mg od for the four-week treatment of non-erosive reflux disease (NERD) with that of placebo od and to investigate safety
Medical condition
Non-erosive reflux disease
Phase
Phase 3
Healthy volunteers
No
Study drug
Omeprazole
Sex
All
Actual Enrollment
270
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Oct 2003
Primary Completion Date: 01 Jul 2004
Study Completion Date: 01 Jul 2004
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Mitsubishi Pharma Corporation
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Medical Science Director
AstraZeneca
